FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma
(MedPage Today) -- Two CAR T-cell therapies for multiple myeloma won favorable recommendations for earlier use in the disease during a day-long meeting of the FDA Oncologic Drugs Advisory Committee (ODAC). By an 11-0 vote, ODAC recommended that... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 17, 2024 Category: American Health Source Type: news

Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma
(MedPage Today) -- An increased risk of early death has created uncertainty about the risk-benefit ratio of two CAR T-cell therapies for relapsed/refractory multiple myeloma, which an FDA advisory committee will consider on Friday. Both ciltacabtagene... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 14, 2024 Category: American Health Source Type: news

Using Patient-Reported Outcomes to Measure Frailty in Patients with Multiple Myeloma
Frailty measures that use patient self-reports called “patient-reported outcomes” (PROs) can provide scientific information on a patient’s experience coming directly from patients. PROs can offer valuable information about a patient’s own health, quality of life, and functional capabilities, (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 12, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

What to Expect From a Stem Cell Transplant
Stem cell transplantation, in combination with traditional treatments, can improve outcomes for patients with multiple myeloma and non-Hodgkin's lymphoma. (Source: WebMD Health)
Source: WebMD Health - March 12, 2024 Category: Consumer Health News Source Type: news

Mayo Clinic Minute: Advances in multiple myeloma treatment
March is Myeloma Awareness Month. Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Black people. Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. And as multiple myeloma research continues, a cure may someday be on… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 12, 2024 Category: Databases & Libraries Source Type: news

Multiple myeloma: Its evolution, treatment and the quest to catch it early
March is Multiple Myeloma Awareness Month. Multiple myeloma is a cancer of a type of white blood cell called a plasma cell in the bone marrow. When multiple myeloma develops in the bone marrow, cancerous plasma cells multiply, crowding out healthy cells. "Over time, people develop abnormalities or mutations in their plasma cells. Those mutations cause plasma cells to become cancerous," says Joselle Cook, M.B.B.S., a Mayo Clinic hematologist specializing in multiple myeloma and other… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 9, 2024 Category: Databases & Libraries Source Type: news

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

' Less Is More' in Myeloma'Less Is More' in Myeloma
Dr. Mohyuddin discusses " less is more " clinical trials that challenge conventional practices and have shown improved outcomes with lower drug dosages.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

‘I feel like myself again’: UCLA clinical trial offers hope for lymphoma patients
In June 2018, actor Hirotaka Matsunaga was supposed to be two weeks away from opening night of “The Swords of Sorrow: BURAI II,” a play set in 1800s Japan. The 39-year-old had been cast as the lead. It was the big break he had been working toward since he moved to the U.S. from Japan more than 20 years ago to pursue his dreams.But his cancer diagnosis and an unsuccessful course of chemotherapy had shut down the play.“Around November 2017, I had acute pain in my stomach for weeks, and it got so bad that it became difficult to eat,” Matsunaga said.After a particularly agonizing dinner, he checked himself into a hosp...
Source: UCLA Newsroom: Health Sciences - March 5, 2024 Category: Universities & Medical Training Source Type: news

The Need for Better Minority Enrollment in Multiple Myeloma Clinical Trials
African Americans are more likely to develop multiple myeloma but are underrepresented in clinical trials. Here’s why and what can be done about it. (Source: WebMD Health)
Source: WebMD Health - March 1, 2024 Category: Consumer Health News Source Type: news

How Is Multiple Myeloma Different for Black and Hispanic Populations?
The blood cancer multiple myeloma affects Black and Hispanic people more often than other groups. A closer look at the reasons behind this disparity. (Source: WebMD Health)
Source: WebMD Health - March 1, 2024 Category: Consumer Health News Source Type: news

The Science Behind the Increased Risk for Black People
A look at possible reasons why multiple myeloma affects Black people more than white people, including genes, health care disparities, and the role of MGUS. (Source: WebMD Health)
Source: WebMD Health - March 1, 2024 Category: Consumer Health News Source Type: news

New Tool Gauges Post –CAR T Relapse Risk in Multiple Myeloma New Tool Gauges Post –CAR T Relapse Risk in Multiple Myeloma
A simple prediction model developed with US and European cohorts effectively predicted relapse risk in multiple myeloma patients post anti-BCMA CAR-T therapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Monthly News Roundup - February 2024
Tecvayli Approved for Biweekly Dosing in Multiple Myeloma In February, the U.S. Food and Drug Administration (FDA) approved biweekly (every 2 weeks) dosing for Tecvayli  (teclistamab-cqyv) in patients with relapsed or refractory multiple... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 29, 2024 Category: Pharmaceuticals Source Type: news

Multiple Myeloma: What Treatments Work Best? Multiple Myeloma: What Treatments Work Best?
The longest overall survival of nearly 8-10 years was with autologous stem cell transplantation.Medscape News UK (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - February 26, 2024 Category: Transplant Surgery Tags: Hematology-Oncology Source Type: news